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Transforming growth factor-b1 hyperexpression in African American
end-stage renal disease patients. End-stage renal disease (ESRD) is more
frequent in African Americans (blacks) compared to Caucasian Ameri-
cans (whites). Identification of remediable causes of the increased preva-
lence has the potential to reduce the excess burden of ESRD. Because
renal fibrosis is a correlate of progressive renal failure and a dominant
feature of ESRD, and because transforming growth factor-beta1 (TGF-b1)
can induce fibrosis and renal insufficiency, we explored the hypothesis that
TGF-b1 hyperexpression is more frequent in black ESRD patients com-
pared to white ESRD patients. Our postulate was tested by determining
circulating levels of TGF-b1 protein in the sera of 56 black and 42 white
ESRD patients treated by chronic hemodialysis. A solid-phase sandwich
enzyme-linked immunosorbent assay, specific for TGF-b1, was used to
quantify TGF-b1 levels in the ESRD cohort. Additional cytokines impli-
cated in tissue repair/remodeling, interleukin-6 (IL-6) and tumor necrosis
factor-alpha (TNF-a), were also measured. Our investigation demon-
strated a significantly higher concentration of TGF-b1 protein but not that
of IL-6 or TNF-a in blacks compared to whites. Our observation that
TGF-b1 is hyperexpressed in black ESRD patients suggests a mechanism
for the increased prevalence of renal failure (since TGF-b1 hyperexpres-
sion can result in renal insufficiency in experimental models) among the
black population.
Irreversible renal failure (that is, end-stage renal disease,
ESRD), a debilitating and costly sequela of most forms of chronic
renal disease, is four times more frequent in African Americans
(blacks) compared to Caucasian Americans (whites) [1]. Whereas
12.5% of the U.S. population is black, more than 31% of patients
requiring dialysis therapy for ESRD are blacks. The three most
common causes of ESRD in the U.S. are diabetes, hypertension
and glomerulonephritis, and all three are more prevalent in the
black population compared to whites. However, the increased
incidence of these diseases fails to fully explain the excess burden
of ESRD among blacks since the age- and gender-adjusted
incidence of ESRD due to hypertension, diabetes or glomerulo-
nephritis is 3- to 10-fold higher in blacks compared to whites [1].
The heightened risk is perhaps best exemplified by the recent data
from two major clinical trials, the Multiple Risk Factor Interven-
tion Trial (MRFIT), and the Modification of Diet in Renal
Disease (MDRD) study. In the MRFIT study, in which black
males and white males with mild to moderate hypertension and
normal renal function were treated with anti-hypertensive medi-
cation, the age-adjusted ESRD incidence was 42.22 per 100,000
person-years in black men and 13.90 per 100,000 person-years in
white men [2]. In the MDRD study, black race was a predictor of
progression of nephropathy [3]. Although several hypotheses have
been proposed to explain these observations, including genetic
differences, increased prevalence of hypertension, and socioeco-
nomic factors, to date these proposed genetic or environmental
factors have not provided a satisfactory or unifying explanation for
the increased risk of ESRD in blacks.
Transforming growth factor-beta1 (TGF-b1), a multifunctional
cytokine with fibrogenic properties, has been implicated in the
pathogenesis as well as the progression of a variety of chronic
renal diseases [4]. In addition to its fibrogenic properties, TGF-b1
has been shown to stimulate endothelin-1 production [5], and thus
may be involved in the pathogenesis of hypertension. In an
attempt to explain the basis for the increased prevalence of ESRD
in the black population, we explored the hypothesis that TGF-b1
hyperexpression is more frequent in black ESRD patients com-
pared to white ESRD patients.
METHODS
End-stage renal disease patient population
Fifty-two black and 46 white patients with ESRD, treated with
chronic hemodialysis therapy, were studied for level of expression
of TGF-b1 protein in their peripheral blood. In addition, circu-
lating levels of interleukin-6 (IL-6) and tumor necrosis factor-
alpha (TNF-a) were also determined in the ESRD cohort.
Interleukin-6 and TNF-a were selected for study because of their
1 See Editorial by Klahr, p 792.
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potent immunoregulatory and remodeling properties [6, 7] and in
consideration of earlier reports of their dysregulated expression in
ESRD patients [8]. All patients were clinically stable and were
free of any active infection. Blood was also drawn from 30 healthy
white and 32 healthy black individuals for cytokine analysis. These
control subjects did not have any history of hypertension, diabe-
tes, renal, cardiovascular, peripheral vascular, or cerebrovascular
disease.
Quantification of cytokine concentration in the serum
Peripheral venous blood was obtained from the patients and the
sera were isolated and stored at 270°C until assayed for cytokines.
The blood samples were drawn prior to the dialysis procedure.
Pre- and well as post-dialysis blood specimens were obtained on
the same day to calculate urea reduction ratio. The biologically-
active TGF-b1 protein concentration was determined using a solid
phase TGF-b1-specific sandwich ELISA (Promega, Madison, WI,
USA), as described [9]. The sera were activated by acidification
and tested at 1:300 dilution, as recommended. A TGF-b1 standard
curve was constructed using 1000, 500, 250, 62.5, 31.25, and 15.6
pg/ml of recombinant human TGF-b1 protein, and a curve-fitting
software program was used to quantify TGF-b1 protein concen-
tration in the sera. The minimum level of detection of TGF-b1
with the sandwich ELISA was 25 pg/ml. ELISA kits (Cytoscreen
immunoassay kit), purchased from Biosource International (Cam-
arillo, CA, USA), were used to measure the concentrations of
IL-6 and TNF-a. Sera were tested at 1:10 dilution and the
minimum detectable concentration was 2 pg/ml for IL-6, and 1
pg/ml for TNF-a.
Statistical analyses
The correlation analysis procedure of SAS (Statistical Analysis
Software Program) [10] was used to calculate Pearson’s correla-
tion coefficients between the variables measured in the ESRD
population. The general linear model (GLM) procedure of SAS
was used for the multivariate linear regression model in which the
TGF-b1 level was considered as the dependent variable, and
several variables such as sex, race, age, albumin, cholesterol and
glucose that were not highly correlative among themselves (by
Pearson’s correlation analysis) were considered as independent
variables.
RESULTS
End-stage renal disease patient characteristics
Diabetes, hypertension and glomerulonephritis were the most
frequent causes of ESRD in our study cohort, as it is in the
general U.S. dialysis population [1]. There were no significant
differences between black and white patients with respect to the
frequencies of the different diseases responsible for their ESRD
(P . 0.05 by Fisher’s exact test). As summarized in Table 1, there
were also no significant differences between black patients and
white patients with respect to age, sex, years on dialysis, serum
electrolytes (Na, K, Cl, HCO3
2, Ca21, PO4
2), serum glutamic-
pyruvic transaminase (SGPT), alkaline phosphatase, albumin,
cholesterol, glucose and hematocrit. Dialysis efficacy, as assessed
by urea reduction ratio [11], was also similar in both groups (Table
1). Plasma creatinine concentration and systolic, diastolic and
mean arterial blood pressures were higher in the black cohort
compared to the white ESRD cohort.
Hyperexpression of transforming growth factor-b1 protein in
the black end-stage renal disease patients
Transforming growth factor-b1 protein was detected in the
peripheral blood of all 98 ESRD patients studied, and the mean 6
SEM TGF-b1 concentration for the entire study group was 174 6
7 ng/ml (median value 5 169 ng/ml). The TGF-b1 protein level
was higher in the black patients compared to their white counter-
parts (Fig. 1). The mean 6 SEM TGF-b1 protein concentration was
207 6 10 ng/ml in the 52 black ESRD patients (median value 5
199 ng/ml); the concentration was 137 6 8 ng/ml in the 46 white
ESRD patients (median value 5 138 ng/ml). The race-dependent
difference in the circulating level of TGF-b1 protein in the ESRD
group was significant at P 5 0.0001 by Student’s t-test.
We determined whether the race-dependent difference in
TGF-b1 protein concentration was demonstrable in male as well
as female ESRD patients. Transforming growth factor-b1 protein
concentrations in black male ESRD patients were significantly
higher than that in white male ESRD patients (197 6 18 ng/ml,
N 5 24 vs. 139 6 12 ng/ml, N 5 27, P 5 0.01). The TGF-b1
protein levels were also significantly higher in black female ESRD
patients compared to white female ESRD patients (215 6 12
ng/ml, N 5 28 vs. 133 6 9 ng/ml, N 5 19, P 5 0.0000). The sex of
the ESRD patients, independent of the race, did not affect
circulating TGF-b1 levels. The mean 6 SEM TGF-b1 protein level
in the males was 166 6 11 ng/ml (N 5 51) and was 182 6 10 ng/ml
in females (N 5 47) (P 5 0.32 by Student’s t-test).
The hemodialysis membranes used in the hemodialyzers can be
characterized as “biocompatible” or “bioincompatible” mem-
branes on the basis of their ability to activate diverse cell types
and/or complement components [12]. The bioincompatible mem-
branes have been implicated in the increased expression of
proinflammatory cytokines such as IL-6 and TNF-a in ESRD
patients [8, 12]. Seventy (38 blacks and 32 whites) of the 98 ESRD
Table 1. Clinical and laboratory features of the end-stage renal disease
(ESRD) patients
Variable
Black
(N 5 52)
Whites
(N 5 46) P valuea
Age 56.9 6 2.1b 61 6 2.3 0.20
Sex (M/F) 24/28 27/19 0.23
Years on hemodialysis 6 6 0.9 4 6 0.7 0.15
Sodium mmol/liter 138 6 0.5 139 6 0.4 0.70
Potassium mmol/liter 4.9 6 0.1 5.0 6 0.09 0.59
Chloride mmol/liter 99 6 0.5 99 6 0.5 0.65
CO2 mmol/liter 23 6 0.5 23 6 0.5 0.86
Glucose mg/dl 117 6 11 119 6 8 0.87
Calcium mg/dl 9.3 6 0.1 9.5 6 0.1 0.76
Phosphate, mgl/dl 6.2 6 0.3 5.7 6 0.3 0.23
AST/SGPT units/liter 16 6 2 15 6 2 0.93
Alk. phosphatase, units/liter 156 6 15 126 6 14 0.11
Albumin g/dl 3.9 6 0.06 4.1 6 0.06 0.07
Cholesterol, mg/dl 171 6 4 173 6 5 0.79
Hematocrit 33.5 6 0.5 33.2 6 0.5 0.51
Urea reduction ratio % 66 6 1 65 6 0.9 0.52
Urea nitrogen mg/dl 66 6 2 74 6 3 0.06
Creatinine mg/dl 11.0 6 0.4 9.2 6 0.4 0.004
Systolic pressure mm Hg 152 6 3 141 6 3 0.03
Diastolic pressure mm Hg 78 6 2 71 6 2 0.004
Mean arterial pressure mm Hg 103 6 2 94 6 2 0.004
a P values based on Student’s t-test for continuous variables and on
Fisher’s exact test for categorical variables.
b mean 6 SEM.
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patients were being dialyzed with the high-flux polysulfone mem-
brane dialyzer (biocompatible dialyzer) and the remaining 28 (14
blacks and 14 whites) were being dialyzed with the cellulose
acetate membrane dialyzer (bioincompatible dialyzer).
We investigated (1) whether the race-dependent difference in
TGF-b1 protein levels is demonstrable in ESRD patients dialyzed
with a biocompatible or a bioincompatible dialyzer, and (2)
whether the type of dialysis membrane influenced TGF-b1 levels.
This analysis demonstrated that black ESRD patients dialyzed
with either type of dialyzer had higher TGF-b1 levels compared to
white ESRD patients dialyzed with a similar dialyzer. Black
ESRD patients dialyzed with a biocompatible dialyzer displayed
significantly higher levels of TGF-b1 compared to white ESRD
patients dialyzed with the biocompatible dialyzer (202 6 13 ng/ml,
N 5 38 vs. 147 6 9, N 5 32, P 5 0.001); black ESRD patients
dialyzed with a bioincompatible dialyzer also had higher levels of
TGF-b1 compared to white ESRD patients dialyzed with the
bioincompatible dialyzer (217 6 17 ng/ml, N 5 14 vs. 111 6 12,
N 5 14, P 5 0.0001). On the other hand, the type of dialyzer,
independent of race, did not influence TGF-b1 protein concen-
tration. The mean 6 SEM level of TGF-b1 protein in the group
(black and white ESRD patients) dialyzed with the biocompatible
dialyzer was 177 6 19 ng/ml (N 5 70) and the mean 6 SEM level
in those dialyzed with the bioincompatible dialyzer was 164 6 14
ng/ml (N 5 28) (P 5 0.11 by Student’s t-test).
The association between TGF-b1 levels and race, and the
correlation between TGF-b1 levels and other clinical and bio-
chemical variables measured in the ESRD cohort were deter-
mined using the correlation analysis procedure of SAS [10]. The
association between TGF-b1 levels and race was highly significant
(correlation coefficient, r 5 0.460, P 5 0.0001); TGF-b1 levels
were also a significant correlate of mean arterial pressure (r 5
0.212, P 5 0.035). Race, in addition to TGF-b1 levels, was also
significantly associated with mean arterial pressure (r 5 0.282,
P 5 0.004) and creatinine (r 5 0.288, P 5 0.004). In contrast,
additional variables such as age, albumin, cholesterol, glucose,
hematocrit, creatinine, blood urea nitrogen, urea reduction ratio,
and years of dialysis therapy were not significant correlates of
TGF-b1 levels.
Multivariate linear regression model of transforming growth
factor-b1 levels in end-stage renal disease patients
In a multivariate linear regression model, TGF-b1 was consid-
ered as the dependent variable, and race and five other variables
(sex, age, albumin, cholesterol, glucose) that did not correlate
with each other (by correlation analysis) were considered as
independent variables. The general linear model procedure of
SAS [10] was used, and Table 2 demonstrates that the race of the
ESRD patient is a significant (P 5 0.0001) determinant of
circulating TGF-b1 protein level in this ESRD cohort.
The general linear model procedure also revealed that addi-
tional renal related variables such as blood urea nitrogen, urea
reduction ratio, serum creatinine, type of dialyzer, or years on
dialysis are not significant determinants of circulating TGF-b1
levels in the ESRD cohort.
Hyperexpression of transforming growth factor-b1 in the black
end-stage renal disease patient is cytokine specific
Interleukin-6 is a multifunctional cytokine implicated in acute
and chronic inflammation [6]. Elevated levels of IL-6 have been
reported in patients with chronic renal failure and in ESRD
patients managed by chronic hemodialysis therapy [8]. Among the
Fig. 1. Differential level of expression of
transforming growth factor-b1 (TGF-b1)
protein in black end-stage renal disease
(ESRD) patients (u) and white ESRD patients
(M). The mean 6 SEM TGF-b1 protein level
was 207 6 10 ng/ml in black ESRD patients
(N 5 52) and 137 6 8 ng/ml in white ESRD
patients (N 5 46) (A). The frequency
distribution of TGF-b1 levels in the ESRD
patients, distinguished by race, is shown in (B).
A total of 96% of the TGF-b1 values from
black ESRD patients were within 2 SD of the
mean value, and the coefficient of skewness and
the coefficient of kurtosis were 0.20 and 0.24,
respectively; 93% of the TGF-b1 values from
white ESRD patients were within 2 SD of the
mean value, and the coefficient of skewness and
the coefficient of kurtosis were 0.38 and 0.78,
respectively. In view of the normal distribution
of TGF-b1 values in the black as well as white
ESRD patients, Student’s t-test was used to
derive the P 5 0.0001 in (A).
Table 2. Multivariate linear regression model of transforming growth
factor-B1 levels in the ESRD cohort
Variable Beta SE 95% CI P value
Intercept 40.191 85.720 2127.81 to 208.202 0.6403
Race 70.040 14.570 41.483 to 98.597 0.0001
Sex 5.065 14.500 223.355 to 33.485 0.7278
Age 0.134 0.460 20.768 to 1.035 0.7731
Albumin 21.488 15.780 232.416 to 29.441 0.9251
Cholesterol 0.050 0.190 20.323 to 0.422 0.8033
Glucose 0.075 0.100 20.121 to 0.271 0.4600
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52 black ESRD patients studied, 7 patients had high levels of IL-6
(32, 40, 102, 240, 307, 405, and . 500 pg/ml), and among the 42
white ESRD patients, high IL-6 levels were detected in 7 patients
(69, 164, 209, 237, 245, 269, and 296 pg/ml). In contrast to the
significant difference between black and white ESRD patients
with respect to TGF-b1 protein levels, circulating IL-6 levels were
not significantly different between the black ESRD patients and
the white ESRD patients.
Tumor necrosis factor-a has been identified as both a circulat-
ing factor as well as a cell-associated cytokine [7]. Implicated in
endotoxic septic shock as well as in cachexia, TNF-a has been
detected in the sera of hemodialysis patients, and TNF-a over-
production by peripheral blood mononuclear cells has been
correlated with an immunocompromised state in ESRD patients
treated with hemodialysis [8, 13]. In the current study, high levels
of TNF-a protein were detected in 4 of 52 black ESRD patients
(22, 25, 35, and . 1000 pg/ml) and in 4 of 46 white patients (53,
53, 95, and 162 pg/ml).
DISCUSSION
The original observation that has emerged from this investiga-
tion is that TGF-b1 is hyperexpressed in black ESRD patients.
Our finding, in view of the multifunctional capabilities of TGF-b1,
supports a new hypothesis for the excess burden of ESRD in the
black population.
Experimental data supporting a pathogenetic role for
transforming growth factor-b1 in progressive renal disease
A participatory role for the 25 kDa homodimeric polypeptide
TGF-b1 in renal fibrosis has been demonstrated in a number of
elegant experimental models. Isaka and colleagues have demon-
strated that in vivo transfection of the TGF-b1 gene (and not that
of the platelet-derived growth factor gene) results in glomerulo-
sclerosis [14]. Akagi and colleagues have shown, in a rat experi-
mental glomerulonephritis model, that a TGF-b1 antisense oli-
gomer reduces the level of intrarenal expression of TGF-b1 and
suppresses extracellular matrix accumulation [15]. In mice with
high levels of circulating TGF-b1 due to a TGF-b1 transgene
under the control of an albumin promoter, mesangial expansion,
glomerular immune deposits, extracellular matrix accumulation,
interstitial fibrosis, and progressive renal disease have all been
observed [16]. Moreover, fatal renal disease occurred in about
25% of the TGF-b1 transgenic mice.
Renal implications of transforming growth factor-b1
hyperexpression in the black end-stage renal disease patients
On the basis of the aforementioned compelling experimental
data and on the basis of information that human renal disease
including chronic renal allograft rejection is distinguished by high
levels of intrarenal expression of TGF-b1 [17–19], we offer the
hypothesis that the heightened risk of progressive renal failure in
the black population is a consequence of increased TGF-b1
protein production (Fig. 2). In this conceptualization, hyperten-
sion, diabetes or intrinsic renal diseases are envisioned as the
initial injury that elicits an exaggerated TGF-b1 response in this
patient population. This excessive reaction, then, results in the
abnormal repair and remodeling that eventually lead to irrevers-
ible renal failure. An exaggerated TGF-b1 response to an injury
rather than a pre-existing high TGF-b1 concentration in the black
population is suggested here in view of our finding that TGF-b1
protein levels in normal blacks and normal whites are quite similar
(68 6 6 ng/ml in 32 normal blacks vs. 64 6 5 ng/ml in 30 normal
whites), while being significantly (P , 0.001) less than that in their
counterparts with ESRD. That the level of expression of TGF-b1
protein distinguishes black ESRD patients from white ESRD
patients but not normal blacks from normal whites is reminiscent
of an earlier observation that plasma endothelin-1 levels are
higher in the black hypertensives compared to white hyperten-
sives, but not in the non-hypertensive blacks compared to whites
[20].
An additional clinical setting in which TGF-b1 may play a role
in a progressive renal disease is human immunodeficiency virus
(HIV) nephropathy, which is significantly more common in blacks
[1]. In this regard, it is noteworthy that TGF-b1 can stimulate the
replication of HIV by several mechanisms [21]. Thus, the height-
ened expression of TGF-b1 might be involved in initiating as well
as perpetuating injury.
Transforming growth factor-b1 hyperexpression: Implications
for hypertension and hypertensive renal disease
Hypertension is more prevalent in blacks compared to whites,
and genetic as well as non-genetic hypotheses have been advanced
to explain this observation [22, 23]. Polymorphisms in a number of
genes related to blood pressure have been reported to be more
common in blacks, including genes for mitochondrial proteins,
angiotensinogen, angiotensin converting enzyme, and the a-2-
adrenergic receptor [23]. In our investigation, TGF-b1 levels
correlated with mean arterial blood pressure. Thus, our identifi-
cation of heightened expression of TGF-b1 in blacks with ESRD
suggests a new mechanism for hypertension in blacks.
How might TGF-b1 contribute to the pathogenesis of hyper-
tension? One potential pathway is via its ability to stimulate the
expression of endothelin-1, a potent vasoconstrictor and a smooth
muscle mitogen [24, 25]. Additional properties of TGF-b1 such as
increased biosynthesis of extracellular matrix components and
Fig. 2. Hypothetical model of transforming growth factor-b1 (TGF-b1)
hyperexpression as a contributory factor for progressive renal insuffi-
ciency. In this hypothesis for the pathogenesis of progressive renal
insufficiency, patients expressing high levels of TGF-b1 in response to
renal injury are at an increased risk for progression. In this formulation,
TGF-b1 expression is engendered by the primary insult (such as diabetes),
and progressive renal insufficiency results from the heightened expression
of TGF-b1. Abbreviations are: DM, diabetes mellitus; GN, glomerulone-
phritis; HT, hypertension; ESRD, end-stage renal disease.
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induction of vascular smooth muscle hypertrophy and fibrocellu-
lar hyperplasia [26, 27] might also contribute to abnormal remod-
eling of the vasculature, narrowing of the vascular lumen and
hypertensive vascular disease.
A perplexing clinical observation has been that aggressive blood
pressure control has not always led to similar renal benefits in
blacks and in whites. Rostand et al have reported that renal
function deteriorated more frequently in hypertensive black pa-
tients compared to hypertensive whites despite similar levels of
blood pressure control [28]. Perry et al have noted a twofold
higher risk of ESRD among black hypertensives compared to
their white counterparts [29]. Recent data from the MRFIT study
have shown that for every level of blood pressure control, blacks
are at an increased risk for the development of renal disease [2].
Thus, the earlier observations [28, 29] and the recent supporting
data from the MRFIT study [2] suggest that there are factor(s) in
addition to hypertension that contribute to the association be-
tween hypertension and ESRD in the black population. Based on
our finding of increased TGF-b1 in blacks with ESRD, and our
observation that TGF-b1 levels correlate with blood pressure, we
suggest that excess expression of TGF-b1 may explain the in-
creased renal morbidity in hypertensive blacks compared with
whites. In this regard it is of interest that a high-salt diet results in
increased TGF-b1 expression and hypertensive renal injury in the
Dahl salt-sensitive rats [30], and that salt-sensitivity of blood
pressure is more frequent in the black hypertensives compared to
white hypertensives (75% vs. 55%) [31]. Also, renovascular resis-
tance is reported to be higher in blacks with essential hypertension
compared to their white counterparts [32], and arterial intimal
fibroplasia is more accelerated in blacks compared to whites [33].
Transforming growth factor-b1 can increase vascular resistance
via stimulation of endothelin-1 expression [5], and facilitate
fibroplasia via its ability to increase extracellular matrix accumu-
lation [3, 4].
Transforming growth factor-b1 hyperexpression: Implications
for end-stage renal disease patient outcome
Survival rates of black ESRD patients treated with chronic
maintenance hemodialysis are higher than that of their white
counterparts [1]. This superior outcome is still apparent after
correction for a number of variables such as age, sex and cause of
renal disease, which have all been shown to influence patient
outcome. The reason(s) for the better outcome is(are) not known.
In view of the observation that TGF-b1 deficiency is associated
with significant coronary artery disease [34], and in light of the
data that cardiovascular disease is a major reason for mortality in
the ESRD population [1], a provocative hypothesis is that the
higher TGF-b1 levels in the black ESRD patients protect, at least
partially, from death due to coronary artery disease. In this
regard, it is noteworthy that the incidence of dialysis-acquired
ischemic heart disease has been reported to be lower in black
ESRD patients compared to white ESRD patients [35], and that
coronary artery disease [36, 37] as well as mortality due to
myocardial infarction [38] are reported to be lower in black men
compared to white men.
Mechanisms for transforming growth factor-b1 hyperexpression
What might be the mechanism for differential levels of TGF-b1
expression? A genetic basis is a distinct possibility. Indeed,
differential levels of expression of cytokines such as TNF-a and
IL-10 have been reported and have been linked to polymorphisms
in the promoter regions of these genes [39–41]. With respect to
the TGF-b1 gene, at least seven polymorphisms have been
identified [42]. However, none of these polymorphisms have yet
been linked to the rate of transcription of TGF-b1 gene or to the
level of expression of TGF-b1 protein.
Our hypothesis implicating TGF-b1 in the pathogenesis of
progressive renal injury in patients with ESRD needs to be
explored with a larger patient base. Moreover, it would be of
interest to correlate TGF-b1 levels and the rate of progression of
renal disease, and test the postulate that high levels of TGF-b1 in
patients with diseases such as diabetes or hypertension, identifies
a priori, patients at risk for progression. The information regard-
ing circulating levels of TGF-b1 might also help guide therapeutic
decisions. For example, blockade of the renin-angiotensin axis
might be more efficacious in patients with high TGF-b1 protein,
since angiotensin II is a potent stimulus for TGF-b1 expression
[43]. Indeed, angiotensin II (Ang II) blockade with a converting
enzyme inhibitor or an Ang II receptor antagonist has been
demonstrated to reduce TGF-b1 mRNA expression as well as
tubulointerstitial fibrosis in a unilateral ureteral obstruction
model [44]. In view of the data demonstrating the beneficial
effects of converting enzyme inhibitors in patients with diabetic
nephropathy [45] as well as in patients with other primary renal
diseases [46], we speculate that therapy-associated decreased
levels of TGF-b1 might be a contributory factor to the salutary
effects of converting enzyme inhibitors in the clinic.
In conclusion, we have demonstrated in vivo hyperexpression of
TGF-b1 in the black ESRD population. In view of the potential of
this multifunctional cytokine to induce renal fibrosis and progres-
sive renal disease, as well as its association with peptides involved
in blood pressure regulation such as endothelin-1 and angiotensin
II, we offer here the hypothesis that heightened TGF-b1 expres-
sion is a mechanism for the increased prevalence of ESRD in the
U.S. black population. Increased TGF-b1 may also contribute
independently to the pathogenesis of hypertension, or it may
contribute to the vascular complications of increased blood pres-
sure. We also suggest that high levels of TGF-b1 in blacks may be
associated with certain beneficial clinical effects such as a lower
incidence of coronary heart disease, and that this may explain the
observations that survival of blacks is better than whites on
hemodialysis. Future studies exploring polymorphisms in the
TGF-b1 gene and their functional consequences might help to
resolve the existing enigma of the increased risk of ESRD in the
U.S. black population, as well as identify a risk factor for
progressive renal disease.
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